• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
              Advocacy & Research for Unlimited Lifespans

- - - - -

CAD-31? A novel Alzheimer’s disease drug candidate..

alzheimers bdnf beta amyloid

  • Please log in to reply
1 reply to this topic

#1 Infinite1

  • Registered User
  • 62 posts
  • 6
  • Location:USA

Posted 10 January 2018 - 05:25 PM

Ran across this article and figured it would be of interest to this group, figured I would share. 


Full text: A novel Alzheimer’s disease drug candidate targeting inflammation and fatty acid metabolism


CAD-31 appears to be an analog of J147 which was initially derived from Curcumin. It looks very promising from looking over this article, not certain about how it would pan out in application-- might be difficult acquiring such a compound. 

  • Informative x 1

#2 prophets

  • Registered User, Advisor
  • 2,163 posts
  • 348
  • Location:US

Posted 10 January 2018 - 07:41 PM

A new study on J147, profiled as an ATP synthase inhibitor and modulator of CAMKK2, which is probably a common pathway shared by resveratrol.


By targeting ATP synthase, J147 causes an increase in intracellular calcium leading to sustained calcium/calmodulin-dependent protein kinase kinase β (CAMKK2)-dependent activation of the AMPK/mTOR pathway, a canonical longevity mechanism



Journal paper source


Goldberg, J., Currais, A., Prior, M., Fischer, W., Chiruta, C., & Ratliff, E. et al. (2018). The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging Cell, e12715. doi:10.1111/acel.12715

sponsored ad

  • Advert
Click HERE to rent this advertising spot for BRAIN HEALTH to support LongeCity (this will replace the google ad above).

Also tagged with one or more of these keywords: alzheimers, bdnf, beta amyloid

0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users